Progress, Potential, and Possibilities Podcast / Show Palestinian-Israeli Cooperation - Spreading Awareness Of Novel Approaches In The War On Cancer
Ms. Suma Khazmo is the CEO, Senior Partner, and Co-Founder of Regal Optics and Medical Devices, which is located in Ramallah / Palestine, which focuses on importing and exporting medical devices into the Middle East and North Africa markets, and owns the Regal-Medic Ophthalmology Clinic. Ms. Khazmo is also a senior partner in Al Hajal Optics Group, a company that has a series of optometry centers in Palestine. She is also the Chairman of the Board of Al Bayader Media and Publishing Corporation. Ms. Khazmo has a Masters Degree in International Relations and a Bachelor's Degree in Media, Journalism, and Political Science, from Birzeit University located in Birzeit, West Bank, near Ramallah. Ms. Khazmo recently became the first International Partner of the World Business Angels Investment Forum (WBAF) to represent Palestine, and became the General Secretary and Health Tech / Healthcare Governor of the Global Startup Ratings Authority (GSRA). Furthermore, Ms. Khazmo has made major contributions in developing Palestinian laws, regulations and legislation; especially in the fields of human rights, environmental laws and animal welfare laws. She has contributed largely to the first Palestinian Animal Welfare Law and is on the advisory board of the Bethlehem Animal and Environment Association. Ms. Khazmo is also a business development / financial consultant for Accelerated Evolution Biotechnologies (AEBI) and spokesperson for MuTaTo, its new comprehensive, multiple target, safe cancer therapy. Dr. Ilan Morad, is the CEO and Founder of the start-up Accelerated Evolution Biotechnologies Ltd. (AEBI), an Israeli company which has developed a novel, combinatorial biology platform focused on developing therapeutics for multiple targets simultaneously, including their lead candidate, called MuTaTo, which stands for "Multi-Target Toxin", being developed as a personalized and comprehensive cancer therapy protocol. Dr. Morad has his MS and PhD from Tel-Aviv University in Biochemistry. Dr. Morad has background in various aspects of the drug discovery / drug development process including gene cloning, protein engineering, purification and characterization.